Compare FLOC & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLOC | WVE |
|---|---|---|
| Founded | 1996 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 855.7M | 744.8M |
| IPO Year | 2024 | 2015 |
| Metric | FLOC | WVE |
|---|---|---|
| Price | $18.96 | $3.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 21 |
| Target Price | ★ $30.56 | $17.22 |
| AVG Volume (30 Days) | 511.8K | ★ 3.0M |
| Earning Date | 11-04-2026 | 11-09-2026 |
| Dividend Yield | ★ 1.91% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $759,719,000.00 | $3,704,000.00 |
| Revenue This Year | $25.40 | $19.15 |
| Revenue Next Year | $14.77 | N/A |
| P/E Ratio | $36.15 | ★ N/A |
| Revenue Growth | 41.93 | ★ 149.43 |
| 52 Week Low | $14.94 | $3.04 |
| 52 Week High | $28.26 | $21.73 |
| Indicator | FLOC | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 44.25 | 26.33 |
| Support Level | $18.66 | N/A |
| Resistance Level | $21.38 | $4.07 |
| Average True Range (ATR) | 0.64 | 0.17 |
| MACD | 0.08 | -0.00 |
| Stochastic Oscillator | 60.53 | 12.14 |
Flowco Holdings Inc is a provider of production optimization, artificial lift, emissions management, and monetization solutions for the oil and natural gas industry. Its technologies include high-pressure gas lift (HPGL), conventional gas lift, plunger lift, and vapor recovery unit (VRU) solutions. The company operates in two reportable segments: Production Solutions, which includes rental services, and Natural Gas Technologies, which include service, gas compression parts, and equipment sales. Production Solutions: relates to rentals, sales, and services related to high-pressure gas lift, conventional gas lift, and plunger lift; including other digital solutions and methane abatement technologies, and has maximum revenue. It generates maximum revenue from the United States.
WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.